Myriad Genetics, Inc.
MYGN
$6.10
$0.437.58%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -330,400.00% | 99.76% | -92.31% | 39.78% | -41.15% |
Total Depreciation and Amortization | -2.08% | -2.70% | -5.13% | 3.31% | -3.82% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 1,882.70% | -131.62% | 303.45% | -45.28% | 115.45% |
Change in Net Operating Assets | -123.14% | 50.00% | -231.51% | -217.39% | 88.83% |
Cash from Operations | 16.56% | -346.97% | 842.86% | -73.08% | 113.98% |
Capital Expenditure | 47.17% | -47.22% | -2.86% | 32.69% | 22.39% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -100.00% | -- | -- |
Other Investing Activities | -36.67% | -30.43% | -204.55% | 283.33% | -200.00% |
Cash from Investing | 16.87% | -40.68% | -178.67% | 217.19% | 9.86% |
Total Debt Issued | -100.00% | 100.00% | 0.00% | 0.00% | -66.67% |
Total Debt Repaid | 99.51% | -5.10% | 2.49% | 0.00% | 66.56% |
Issuance of Common Stock | -- | -- | -- | -100.00% | -- |
Repurchase of Common Stock | 100.00% | -383.33% | 60.00% | -500.00% | 94.25% |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -80.88% | 547.62% | 167.74% | -229.17% | 127.27% |
Foreign Exchange rate Adjustments | 500.00% | 114.29% | -158.33% | 271.43% | 12.50% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | 200.00% | -- |
Net Change in Cash | -58.72% | -619.05% | -75.58% | 295.45% | 87.54% |